Post Marketing Clinical Follow up Study of HyaleXo

NCT07096050 | Completed

• 1 other identifier: YYDATP-PMCF-RO
• Study Type: interventional
• Target: 101
• Locations: 1 country
• Sites: 1

Brief Summary

Hyaluronic acid is a polysaccharide naturally present in several human tissues such as cartilage. It is the major constituent of synovial fluid and provides its viscosity and elasticity. In traumatic and degenerative joint diseases, the amount of hyaluronic acid is reduced. The consequent loss of viscosity by the synovial fluid may be the cause of painful symptoms. HyaleXo action, according to its composition (sodium hyaluronate of very high molecular weight), may restore the viscoelastic properties of synovial fluid, attenuate pain and improve the mobility of the joint. These characteristics allow HyaleXo to be used for the symptomatic relief of pain in patients suffering from osteoarthritis (OA) or degenerative joint diseases causing an alteration of the functionality of the synovial fluid. The patient will be treated with HyaleXo as reported in the Instruction for use (IFU) of the device: via injection once a week for 3 weeks using standard technique. The patient pain management strategy should be according to the standard clinical practices and remains at the discretion of the investigator. The Research Question of the present study is the following: in a population of men and women suffering from painful knee osteoarthritis or degenerative joint disease will very high molecular weight fraction of sodium Hyaluronate (HyaleXo) significantly decrease and / or relieve the pain after 1,6,12 weeks and 6 months of the third injection?

Conditions

Knee Osteoarthritis

Outcome Measures

Primary Outcomes (1)

• Functional assessment of HyaleXo by KOOS

  Functional assessment of HyaleXo by KOOS (Knee Injury and Osteoarthritis Outcome score) for Pain subscale at 12 weeks after the last administration of the investigational product, compared to the baseline.

  12 weeks

Secondary Outcomes (6)

• Functional assessment of HyaleXo by KOOS

  1,6,12 weeks and 6 months

• Functional assessment of HyaleXo by KOOS

  1,6 weeks and 6 months

• Visual Analgoue Sclae

  1,6,12 weeks and 6 months

• Visual Analgoue Sclae

  1,6,12 weeks and 6 months

• Visual Analgoue Sclae

  1,6,12 weeks and 6 months

Study Arms (1)

Patients that meet inclusion/exclusion criteria.

OTHER

Patients that meet inclusion/exclusion criteria.

Other: HyaleXo

Interventions

HyaleXo OTHER

Treatment of HyaleXo 3 times

Patients that meet inclusion/exclusion criteria.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients older than 18 years old (inclusive ≥ 18 years).
• Men or women.
• Patients suffering from painful chronic idiopathic symptomatic degenerative joint diseases (clinical evidence) OR knee osteoarthritis (as defined by the American College of Rheumatology (ACR) criteria); for patients with OA at both knees, only the most painful one will be included in the study.
• VAS knee pain ≥ 40 mm at screening and 30 days before.
• Patients willing and able to comply with study terms.
• Patients willing to discontinue all other OA treatments

You may not qualify if:

• Patients that are unable or unwilling to provide informed consent, and/or patients participating in a concurrent clinical trial and/or patients who have participated in a similar clinical trial within the last days.
• Patients with known hypersensitivity to any components of investigational product.
• Patients who are pregnant or breastfeeding. Patients with infected or severely inflamed joints.
• Patients with skin diseases or infections in the area of the injection site.
• Patients with hepatic failure or history thereof.

Sponsors & Collaborators

• Yooyoung Pharmaceutical Co., Ltd.: lead
• TigerMed: collaborator

Study Sites (1)

Echipa Medical 33

Timișoara, 30, Romania

Location

MeSH Terms

Conditions

Osteoarthritis, Knee

Condition Hierarchy (Ancestors)

Osteoarthritis; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 24, 2025
• First Posted: July 31, 2025
• Study Start: August 2, 2024
• Primary Completion: February 14, 2025
• Study Completion: April 25, 2025
• Last Updated: July 31, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

RO (1)